Remember these two statements?
“Demonstrates remarkable efficacy and safety in the treatment of adolescent depression.”
“The results of the studies were disappointing. The possibility of obtaining a safety statement from this data was considered but rejected.”
The first is what Glaxo (GSK) told its sales reps after it tested Seroxat, an adult antidepressant on teenagers. The second is what company insiders had admitted internally.
But Glaxo went ahead and promoted Seroxat (Paxil) for children anyway.